Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.67 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 3/20 | 0.53 |
| ▸ | CCR1 | P32246 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183289 | 0.85 | NPC1 (0.60) | KDM1APTGES2CCR2CCR1ALDH1A1 | |
| SCHEMBL4192989 | 0.82 | MCL1 (0.70) | MCL1PTGES2ALDH1A1LMNAGLA | |
| SCHEMBL10826418 | 0.81 | KDM1A (0.62) | MCL1KDM1ACCR2CCR1LMNA | |
| SCHEMBL10702348 | 0.80 | MCL1 (0.70) | MCL1ALDH1A1LMNAGLAL3MBTL1 | |
| SCHEMBL7588697 | 0.79 | PTGES2 (0.74) | KDM1APTGES2LMNAMEN1MAPT | |
| SCHEMBL30450095 | 0.79 | MCL1 (0.72) | MCL1KDM1ACCR2CCR1ALDH1A1 | |
| SCHEMBL15228439 | 0.79 | MCL1 (0.72) | MCL1KDM1ACCR2CCR1ALDH1A1 | |
| SCHEMBL7580383 | 0.79 | MCL1 (0.68) | MCL1PTGES2CCR2CCR1LMNA | |
| SCHEMBL4192981 | 0.78 | MCL1 (0.60) | MCL1KDM1AALDH1A1LMNAGLA | |
| SCHEMBL7593595 | 0.77 | CCR9 (0.62) | MCL1KDM1APTGES2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | MCL1 2757/4885KDM1A 3427/4885PTGES2 3192/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | MCL1 2757/4885KDM1A 3427/4885PTGES2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.